AstraZeneca’s experimental COVID-19 antibody drug cocktail succeeds in large-stage study

AstraZeneca’s experimental COVID-19 antibody drug cocktail succeeded in reducing severe disease or death in non-hospitalised patients in a late-stage study, the British drugmaker says.

The drug, called AZD7442, reduced the risk of developing severe COVID-19 or death by 50 per cent in patients…